Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

CSPC Pharmaceutical Group

Status and phase: Completed; Phase 1

Conditions: Asthma; Allergic Rhinitis

Treatments: Drug: CSPCHA115 100 mg; Matching placebo 100 mg; Drug: CSPCHA115 200 mg; Matching placebo 200 mg; Drug: CSPCHA115 600 mg; Matching placebo 600 mg; Drug: CSPCHA115 400 mg; Matching placebo 400 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT04161547

HA116201903/PRO I-MAD

Details and patient eligibility

About

A randomized, single-center, double-blind, ascending multiple-dose, placebo-controlled study to evaluate the tolerability and pharmacokinetics of CSPCHA115 capsules in Chinese healthy volunteers.

Enrollment: 40 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 ≤ age ≤ 45 years old, male or female;
• Bodyweight≥45.0 kg (female) or 50.0 kg (male), 19 kg/m^2 ≤ Body Mass Index（BMI ）≤ 26 kg/m^2;
• The female subjects are not during pregnancy or lactation; the male subjects have no sperm donation plan from the signing of the informed consent form to 1 month after the completion of the study. The subjects and their partners agree to use effective non-hormonal contraceptives (such as condoms, drug-free IUDs, etc.) from the day signing the informed consent form to 1 month after the completion of the study, or had taken permanent contraceptives (such as bilateral tubal ligation, vasectomy, etc.);
• Subjects voluntarily sign the informed consent form, and are able to complete the trial according to the protocol;

Exclusion criteria

Those who conform to one of the following provisions shall not be included in the group;

• A clear history of neurological or mental disorders (including seizures, dementia, depression or biphasic affective disorders, etc.); immunodeficient or immunosuppressive diseases, malignant tumor diseases; cardiovascular, liver and kidney, endocrine, respiratory, blood, digestive system and other chronic diseases;
• Subjects who underwent large surgical operations within 6 months before signing the informed consent (such as coronary artery bypass grafting, hepatorenectomy, nephrectomy, gynecological surgery, etc.), and those with acute neurological, digestive, respiratory, circulation, endocrine, blood and other systemic diseases within 3 months before signing the informed consent form may affect the absorption, distribution, metabolism and excretion of drugs;
• Subjects with allergic constitutions, or who are allergic to more than 1 drug, or had other known serious allergic reactions;
• Subjects who did not meet the health criteria during the screening period, including abnormal vital signs; QTc interval ≥ 450 ms (male) or 470ms (female), prolongation of QTc interval, or other abnormal clinical significance of electrocardiogram (ECG); the results of physical examination, laboratory examination and so on are abnormal and have clinical significance.
• One of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), human immunodeficiency virus antibody (Anti-HIV) and Treponema pallidum antibody (Anti-TP) was positive;
• Any prescription drugs, non-prescription drugs, biological products, the Chinese patent medicines, herbs, vitamin dietary supplements, and health-care products (other than external use), oral long-acting contraceptives or embedded long-acting contraceptives were used regularly within 2 weeks before the signing of the informed consent form;
• A history of alcoholism, or alcohol test positive at screening;
• The average daily smoking volume was more than 5 within 6 months before signing the informed consent form;
• Drug abuse within 1 year before signing the informed consent form, or urine test positive for drugs at screening;
• Subjects who were accustomed to excessive caffeine drinks or foods that may affect drug metabolism within 4 weeks prior to the signing of the informed consent form;
• Subjects who lost blood or donated more than 200 ml within 8 weeks before signing the informed consent form, or who planned to donate blood within 1 month after the completion of the study;
• Subjects who plan to undergo surgery during the trial period, or those who plan to take part in strenuous exercise during the trial period;
• Subjects who are participating in other clinical trials, or who have participated in clinical trial about any other drugs or devices within 3 months before signing the informed consent form;
• Not suitable for this clinical trial judged by the investigators.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Quadruple Blind

---

40 participants in 4 patient groups

Cohort A1: CSPCHA115 100 mg

Experimental group

Description:

CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days. * Eight subjects will receive CSPCHA115 * Two subjects will receive matching placebo

Treatment:

Drug: CSPCHA115 100 mg; Matching placebo 100 mg

Cohort A2: CSPCHA115 200 mg

Experimental group

Description:

CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days. * Eight subjects will receive CSPCHA115 * Two subjects will receive matching placebo

Treatment:

Drug: CSPCHA115 200 mg; Matching placebo 200 mg

Cohort A3: CSPCHA115 400 mg

Experimental group

Description:

CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days. * Eight subjects will receive CSPCHA115 * Two subjects will receive matching placebo

Treatment:

Drug: CSPCHA115 400 mg; Matching placebo 400 mg

Cohort A4: CSPCHA115 600 mg

Experimental group

Description:

CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days. * Eight subjects will receive CSPCHA115 * Two subjects will receive matching placebo

Treatment:

Drug: CSPCHA115 600 mg; Matching placebo 600 mg